A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase II/III
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary) ; Ustekinumab; Ustekinumab
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms GALAXI; GALAXI 1; GALAXI 2; GALAXI 3
- Sponsors Janssen Research & Development
- 11 Jul 2018 Planned primary completion date changed from 16 Aug 2022 to 3 Jun 2022.
- 15 Jun 2018 Planned End Date changed from 23 Oct 2024 to 2 Nov 2024.
- 15 Jun 2018 Planned primary completion date changed from 3 Jun 2022 to 16 Aug 2022.